Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yanling Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8780-986X; OpenAlex author ID A5100393659. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. A novel defined cuproptosis-related signature score to predict prognosis and immunotherapy efficacy in pancreatic cancer. Last author DOI 10.3892/ol.2025.15337↗
  2. The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Co-author DOI 10.1007/s00262-024-03644-2↗
  3. Correction to: The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy. Co-author DOI 10.1007/s00262-024-03739-w↗
  4. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Co-author DOI 10.1016/j.canlet.2023.216095↗
  5. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
  6. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2022.942225↗
  7. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized … Co-author DOI 10.7150/jca.26672↗
  8. Diagnostic Value of CA 19-9 and Carcinoembryonic Antigen for Pancreatic Cancer: A Meta-Analysis. Co-author DOI 10.1155/2018/8704751↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengbai Xue · 5 shared papers, 2022–2024 · strength 0.81
  2. Weiyu Ge · 4 shared papers, 2022–2025 · strength 0.74
  3. Liwei Wang · 4 shared papers, 2022–2024 · strength 0.67
  4. Xiaofei Zhang · 3 shared papers, 2022–2023 · strength 0.41
  5. Tiebo Mao · 3 shared papers, 2022–2023 · strength 0.41
  6. Jiujie Cui · 3 shared papers, 2022–2023 · strength 0.41
  7. Qing Xia · 2 shared papers, 2024 · strength 0.40
  8. Wenxin Lu · 2 shared papers, 2024 · strength 0.40
  9. Jiayu Yao · 2 shared papers, 2022 · strength 0.26
  10. Yu Wang · 1 shared paper, 2024 · strength 0.20
  11. Haibo Xing · 2 shared papers, 2018–2019 · strength 0.19
  12. Mengting Tong · 2 shared papers, 2018–2019 · strength 0.19
  13. Liwei Wang · 1 shared paper, 2023 · strength 0.15
  14. Da Li · 1 shared paper, 2019 · strength 0.10
  15. Da Li · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.